Shrushma Loi
0000-0002-3815-2320
1 paper found
Refreshing results…
Six versus 12 months’ adjuvant trastuzumab in patients with HER2-positive early breast cancer: the PERSEPHONE non-inferiority RCT
Missing publications? Search for publications with a matching author name.